Thomas LeBlanc, MD, MA

Duke Cancer Center

Latest Videos

Group photo of five medical professionals discussing personalized therapy decisions in myelodysplastic syndromes.

Evolving Approaches: Low-Risk MDS

08/07/2026

Ep. 4: Personalizing Therapy Decisions in Lower-Risk Myelodysplastic Syndromes

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Panel of five medical experts discussing managing imetelstat toxicities in lower-risk MDS during OncUpdates episode 3.

Evolving Approaches: Low-Risk MDS

08/04/2026

Ep. 3: Managing Imetelstat Toxicities in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Panel of five medical experts discussing treatment sequencing in lower-risk MDS at OncUpdates.

Evolving Approaches: Low-Risk MDS

08/01/2026

Ep. 2: Imetelstat, Luspatercept, and ESAs: Treatment Sequencing in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Group photo of five medical professionals discussing next-generation sequencing and IPSS-M in lower-risk MDS for OncUpdates episode 1.

Evolving Approaches: Low-Risk MDS

07/29/2026

Ep. 1: The Growing Role of Next-Generation Sequencing and IPSS-M in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Evolving approaches in low-risk myelodysplastic syndromes with expert doctors Dr. Yasmin Abaza, Dr. Thomas LeBlanc, Dr. Hetty Carraway, Dr. Rahul Gosain, and Dr. Amer Zeidan.

Evolving Approaches: Low-Risk MDS

07/28/2026

The Role of Imetelstat in Lower-Risk Myelodysplastic Syndromes

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD